Dostarlimab, monoclonal antibody, small colorectal cancer trial "cancer vanished in every patient"

48 Просмотры
Издатель
Miraculously In Patients For First Time In Medical History
Dostarlimab, a drug was given in a small clinical trial to 18 patients for around six months, and in the end, it was found that cancer had just vanished away miraculously in every patient, as per NYT report.

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as a medication for the treatment of endometrial cancer.

Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.

On 5 June 2022, a paper was published reporting a study of 12 patients with mismatch repair–deficient (dMMR) stage II or III rectal adenocarcinoma due to microsatellite instability. After six months of treatment the cancer was undetectable by physical exam, endoscopy, PET scans, or MRI scans in all 12 patients. The cancer has remained undetectable in all patients, including one followed for 25 months, however it was not indicated for most forms of colorectal cancer.

Dostarlimab was approved for medical use in the United States and in the European Union in April 2021.

The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation. Additional common side effects reported in the EU include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low levels of thyroid hormones).
Категория
Рак ЖКТ
Комментариев нет.